{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-072531","form_type":"8-K","ticker":"RNLXY","cik":"0001811115","company_name":"Renalytix plc","filed_at":"2024-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.267008+00:00","generated_at":"2026-06-01T04:53:12.922059+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Appoints Joel Jung as Interim CFO with $8k/month salary and 60k options","bullets":["Interim CFO Joel Jung receives $8,000 monthly base salary under consulting agreement.","Option grant of 60,000 ordinary shares; 1/4 vest Aug 28, 2024, rest monthly over 9 months.","Exercise price equals closing price of ordinary shares on AIM on day before grant.","Options fully vest upon change in control; agreement terminable with 3 months' notice."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-072531","json":"https://secwatch.observer/filing/0000950170-24-072531.json","markdown":"https://secwatch.observer/filing/0000950170-24-072531.md","text":"https://secwatch.observer/filing/0000950170-24-072531.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024072531/0000950170-24-072531-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024072531/rnlx-20240607.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:53:12.922059+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a5df8ea4ce","claim":"Joel R. Jung was appointed as Interim Chief Financial Officer at Renalytix plc.","evidence_excerpt":"announcing the appointment, on May 27, 2024, of Joel R. Jung as Interim Chief Financial Officer of the Company in connection with O. James Sterling’s resignation from his position with the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024072531/0000950170-24-072531-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"eca3876f42","claim":"O. James Sterling resigned as Chief Financial Officer at Renalytix plc.","evidence_excerpt":"announcing the appointment, on May 27, 2024, of Joel R. Jung as Interim Chief Financial Officer of the Company in connection with O. James Sterling’s resignation from his position with the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1811115/000095017024072531/0000950170-24-072531-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}